about
The Prognostic Role of Red Blood Cell Distribution Width in Coronary Artery Disease: A Review of the PathophysiologyEffects of direct stenting on epicardial and myocardial perfusion in patients with acute ST segment elevation myocardial infarction[Acute coronary syndrome in Opole region. Data from the National Registry of Acute Coronary Syndrome PL-ACS].[Treatment results of patients with acute coronary syndrome. Data form the National Registry of Acute Coronary Syndrome PL-ACS].[Myocardial infarction with non-ST-segment elevation. Data from the the National Registry of Acute Coronary Syndrome PL-ACS in Silesia].[Treatment results of myocardial infarction with ST-segment elevation. Data from the the National Registry of Acute Coronary Syndrome PL-ACS in Silesia].[Treatment results of myocardial infarction with ST-segment elevation complicated by cardiogenic shock. Data from the the National Registry of Acute Coronary Syndrome PL-ACS in Silesia].[Surgical revascularization in acute coronary syndrome. Data from the the National Registry of Acute Coronary Syndrome PL-ACS in Silesia].[Female-male. Can they be treated the the same way? Primary analysis of data from the National Registry of Acute Coronary Syndrome PL-ACS].Red cell distribution width is associated with long-term prognosis in patients with stable coronary artery disease.What has changed in the treatment of ST-segment elevation myocardial infarction in Poland in 2003-2009? Data from the Polish Registry of Acute Coronary Syndromes (PL-ACS).The obesity paradox in acute coronary syndrome: a meta-analysisThe influence of diabetes on in-hospital and long-term mortality in patients with myocardial infarction complicated by cardiogenic shock: results from the PL-ACS registry.The Relationships between Polymorphisms in Genes Encoding the Growth Factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the Restenosis Process in Patients with Stable Coronary Artery Disease Treated with Bare Metal Stent.The association of functional polymorphisms in genes encoding growth factors for endothelial cells and smooth muscle cells with the severity of coronary artery disease.Clinical characteristics, treatment, and prognosis of patients with ischemic and nonischemic acute severe heart failure. Analysis of data from the COMMIT‑AHF registry.Acute myocardial infarction due to left main coronary artery disease in men and women: does ST-segment elevation matter?Higher mortality in women after ST-segment elevation myocardial infarction in very young patientsST-segment elevation myocardial infarction in women with type 2 diabetes.Percutaneous coronary intervention in treatment of multivessel coronary artery disease in patients with non-ST-segment elevation acute coronary syndromeTrends in sex differences in clinical characteristics, treatment strategies, and mortality in patients with ST-elevation myocardial infarction in Poland from 2005 to 2011.Direct Admission Versus Interhospital Transfer for Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction.Low platelet activity predicts 30 days mortality in patients undergoing heart surgery.Renal function on admission affects both treatment strategy and long-term outcomes of patients with myocardial infarction (from Polish Registry of Acute Coronary Syndromes).Medium platelet volume as a noninvasive predictor of chronic total occlusion in non-infarct artery in patients with non-ST-segment elevation myocardial infarction and multivessel coronary artery disease.Comparison of Inhospital and 12- and 36-Month Outcomes After Acute Coronary Syndrome in Men Versus Women <40 Years (from the PL-ACS Registry).COnteMporary Modalities In Treatment of Heart Failure: a report from the COMMIT-HF registry.Safety and efficacy of a second-generation coronary sirolimus-eluting stent with biodegradable polymers in daily clinical practice: a 12-month follow-up of the ALEX registry.Total coronary occlusion of infarct-related arteries in patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary revascularisation.Post-procedural TIMI flow grade 2 is not associated with improved prognosis in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary revascularization (PL-ACS registry).[Myocardial infarction due to the left main coronary artery disease in men and women--does accompanying multivessel disease matter?].[Non ST-segment elevation myocardial infarction in men and women with diabetes mellitus].Relationship between low-density lipoprotein cholesterol level on admission and in-hospital mortality in patients with ST-segment elevation myocardial infarction, with or without diabetes, treated with percutaneous coronary intervention.Blood glucose level on admission determines in-hospital and long-term mortality in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock treated with percutaneous coronary intervention.Progression of coronary artery atherosclerosis after acute myocardial infarction: an angiographic study.Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction.Acute myocardial infarction due to left main coronary artery disease: a large multicenter national registry.Impact of chronic total occlusion artery on 12-month mortality in patients with non-ST-segment elevation myocardial infarction treated by percutaneous coronary intervention (from the PL-ACS Registry).Mortality of patients with ST-segment elevation myocardial infarction and cardiogenic shock treated by PCI is correlated to the infarct-related artery--results from the PL-ACS Registry.Comparison of early and long-term results of percutaneous coronary interventions in patients with ST elevation myocardial infarction, complicated or not by cardiogenic shock.
P50
Q26785682-A3781446-F072-4166-A30E-7B99745B3F9CQ28213542-29967131-DB21-4BBC-987D-7BFCF37E871BQ33509074-B18F3C77-E942-4D93-A142-2C5A798F680CQ33509076-30BC3CE1-8DDD-4366-905E-57CDD06C5942Q33509077-8C8D4B3E-D717-493F-8339-07323D29B914Q33509079-80631ED8-5602-41D5-92D7-6A15D96D607DQ33509080-EDA31114-49CB-4BF3-BFE8-479014C9AB85Q33509082-CE654283-32BF-47B4-AE0E-1193323ABFD6Q33509083-D2D60CBC-0A00-4818-BB08-78930B02E06BQ33641597-7E014BF2-92BB-43C9-A399-036705900E6FQ34076312-8B577A5C-D4E1-4C82-A791-EDF71CF7A705Q34445415-46758970-F776-4513-B7F6-2F7FA4F58A76Q34646773-8A9B38FF-8ED7-42D2-B310-FD3F72BA0508Q35941138-23B7007E-A782-43E6-8BCD-C4F541B0AB9AQ36190216-5998AC65-0B2D-41D5-A817-32689687A627Q36350408-3D58EBB7-94DC-41F8-BAE6-9F0CDC914698Q36418993-DD28CD8C-EE9B-43CB-B8A4-C856CBD447F1Q36983995-01129024-F0C7-4C11-9D33-A765538940ACQ37278019-7E088624-BDCF-410F-A1B0-2FF72C810F12Q37561885-65E4C69B-088E-444A-99F5-E34C8EC97D66Q38794198-F7085860-FD88-4F32-8008-793CA78E5E93Q38952941-4EF3B748-F35C-4B0C-AFEC-77E22CD4CA5BQ38964311-D7EB1746-5B8A-45A1-A9AD-D08188D47F4DQ38985043-DDCE0671-C9C5-4E94-B222-097C97848FE1Q39152506-E9243555-C5D2-4195-A871-1BB0C0E1FE41Q39402692-5F4E94F2-078A-4824-9C15-026CC92F88A3Q40286400-D9B3439B-CB29-4CB0-87C3-1CD164B9642FQ40308473-A25B5F22-A7A9-48B4-A5A1-6C670EF0EB88Q40551054-2D360E94-34C2-4D01-8FBB-07A058DDBAE7Q40703782-752238BF-1B51-4C22-8599-4B11635C2183Q41236821-4AAE628B-F1AC-4F1D-99A5-EF9DC269D250Q41236831-04C20C33-99FF-4360-A0F5-C3B544D574F0Q42880137-082B4C51-AD87-49AD-911F-CFAA9453A34DQ42963135-69559884-1B96-43EE-B3EE-CF93FDA19D27Q43075302-15A4CFB4-1420-4E24-9AB2-1DE5780FB967Q43453130-A00D6252-F9D8-46BB-83DD-028D12A2CF34Q43468772-C7FB7845-B524-4105-A53F-0BD5564C3328Q43498869-B709FA7F-941B-46F3-BEDB-F02D587B8052Q43547905-F592B894-0303-4DBB-9E81-31D966703BE1Q43741415-EBC39FCB-34CC-42D3-A852-3EF6423FD67B
P50
description
Polish cardiologist
@en
Pools onderzoeker
@nl
cairdeolaí Polannach
@ga
polski lekarz, kardiolog
@pl
հետազոտող
@hy
name
Marek Gierlotka
@ast
Marek Gierlotka
@ca
Marek Gierlotka
@cs
Marek Gierlotka
@en
Marek Gierlotka
@es
Marek Gierlotka
@ga
Marek Gierlotka
@gl
Marek Gierlotka
@hr
Marek Gierlotka
@hsb
Marek Gierlotka
@it
type
label
Marek Gierlotka
@ast
Marek Gierlotka
@ca
Marek Gierlotka
@cs
Marek Gierlotka
@en
Marek Gierlotka
@es
Marek Gierlotka
@ga
Marek Gierlotka
@gl
Marek Gierlotka
@hr
Marek Gierlotka
@hsb
Marek Gierlotka
@it
prefLabel
Marek Gierlotka
@ast
Marek Gierlotka
@ca
Marek Gierlotka
@cs
Marek Gierlotka
@en
Marek Gierlotka
@es
Marek Gierlotka
@ga
Marek Gierlotka
@gl
Marek Gierlotka
@hr
Marek Gierlotka
@hsb
Marek Gierlotka
@it
P106
P1153
6603404059
P1412
P1559
Marek Gierlotka
@pl
P21
P214
2041152684007823430001
P27
P31
P3124
P496
0000-0001-5639-2128
P735
P7859
viaf-2041152684007823430001